

## **COMMITTEE ON TOXICITY OF CHEMICALS IN FOOD, CONSUMER PRODUCTS AND THE ENVIRONMENT**

### **Second draft statement on the potential risks from hexabromocyclododecanes (HBCDDs) in the infant diet**

#### **Introduction**

- 1) The Committee on Toxicity (COT) has been asked to consider aspects related to the toxicity of chemicals in food, in support of a review by the Scientific Advisory Committee on Nutrition (SACN) of Government recommendations on complementary and young child feeding. Members concluded that brominated flame retardants (BFRs) should be considered as part of that body of work. 1,2,5,6,9,10-Hexabromocyclododecanes (HBCDDs, sometimes also abbreviated as HBCDs) are widely used as an additive flame retardant in fabrics and polystyrene products. A scoping paper (TOX2014/24) was presented to Members in September 2014. A first draft statement summarising the available information, taking into account the previous discussion was presented to Members in December 2014 (TOX/2014/35).
- 2) Annex A contains a second draft COT statement based on the previous draft and suggested amendments

#### **Questions on which the views of the Committee are sought**

- 3) Do Members agree with the statement in paragraph 20 that “the effects of HBCDDs on the thyroid hormone axis were likely to be secondary to increased hepatic clearance of T4 via glucuronidation”.
- 4) Members are invited to agree the content of the second draft statement.

**Secretariat  
January 2015**

## COMMITTEE ON TOXICITY OF CHEMICALS IN FOOD, CONSUMER PRODUCTS AND THE ENVIRONMENT

### Second draft statement on the potential risks from hexabromocyclododecanes (HBCDDs) in the infant diet

#### Background

1. The Scientific Advisory Committee on Nutrition (SACN) is undertaking a review of scientific evidence that bears on the Government's dietary recommendations for infants and young children. The review will identify new evidence that has emerged since the Government's current recommendations were formulated, and will appraise that evidence to determine whether the advice should be revised. The recommendations cover diet from birth to age five years, but will be considered in two stages, focussing first on infants aged 0 – 12 months, and then on advice for children aged 1 to 5 years. SACN is examining the nutritional basis of the advice, and has asked that evidence on possible adverse effects of diet should be considered by other advisory committees with relevant expertise. SACN asked COT to review the risks of toxicity from chemicals in the infant diet.
2. This statement gives an overview of the potential risks from 1,2,5,6,9,10-hexabromocyclododecanes (HBCDDs, sometimes also abbreviated as HBCDs) in the infant diet. None of Government's current dietary recommendations for infants and young children relates to HBCDDs.
3. HBCDDs have a molecular structure in the form of a 12-carbon ring substituted with 6 bromine atoms. All HBCDDs share the same chemical formula but differ from one another in the arrangement of bromine atoms around the 12-carbon ring. There are 16 structural isomers, which can be grouped into 8 diastereomeric pairs of enantiomers. Technical mixtures of HBCDDs have been widely used as additive flame retardants in fabrics and in polystyrene products in the building and electronics industries.
4. Technical HBCDD comprises mainly the three diastereomeric pairs of enantiomers, designated  $\alpha$ ,  $\beta$  and  $\gamma$  (Figure 1), in the approximate proportions, 9-13%  $\alpha$ , <0.5-12%  $\beta$  and 72-90%  $\gamma$  (EFSA, 2011). However, in environmental media and biological material, the relative proportions are altered, with the  $\alpha$  isomer predominating at the expense of the  $\gamma$ . This isomeric shift is partly a consequence of the heating process that is used when HBCDDs are applied to the material which they are to protect, but other mechanisms such as differential absorption and metabolism cannot be ruled out.

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.




Figure 1: Structures of the main isomers in technical HBCDD

5. The physicochemical properties of HBCDDs, especially their stability and lipophilicity, along with their large volume of annual production, ubiquitous use and the fact that they do not bind to the materials in which they are incorporated, have all contributed to their becoming widely distributed in the environment and entering the food chain. HBCDDs have been added to Annex A of the Stockholm Convention on Persistent Organic Pollutants and their use for all but construction purposes was banned on 26th November 2014. (C.N.934.2013.TREATIES-XXVII.15 (Depositary Notification)) However since they were already widely distributed in the environment and consumer products, human exposure will persist beyond the ban.

## Previous evaluations by COT and EFSA

### COT

6. COT, in a statement on brominated flame retardants in fish from the Skerne-Tees rivers system (2004)<sup>1</sup>, concluded that uncertainties and deficiencies in the toxicological databases for HBCDDs precluded specification of tolerable daily intakes (TDIs), and therefore adopted a Margin of Exposure (MOE) approach to risk assessment. The Committee observed that all toxicological studies of HBCDDs had been conducted using technical (commercial) mixtures, and that the composition of the material used in many of the studies was unclear and likely to differ from the mixture of isomers encountered in food and the environment. HBCDDs were noted to be hepatotoxic, but there had been no evidence of developmental toxicity in routine studies. One study, available only in abstract form, indicated that HBCDDs might cause neurodevelopmental effects but there was insufficient detail for the finding to be used in quantitative risk assessment. A lowest observed adverse effect level (LOAEL) of 100 mg/kg, for increased liver weight and disturbances in thyroid hormones, was used as a point of departure in the calculation of MOEs.

<sup>1</sup> <http://cot.food.gov.uk/cotstatements/cotstatementsyrs/cotstatements2004/cotstatementbfrfish2004>

## **EFSA**

7. EFSA (2011) noted that orally administered HBCDDs were readily absorbed, but with some differences between stereoisomers.  $\alpha$ -HBCDD was reported to concentrate in adipose tissue. Debromination and hydroxylation were the major routes of metabolism. Stereoisomerisation of  $\gamma$ -HBCDD to the  $\alpha$ - and  $\beta$ -isomers was observed in mice, but stereoisomerisation of  $\alpha$ -HBCDD had not been reported. Elimination half-lives in mice varied from 3-4 days for  $\gamma$ -HBCDD to 17 days for  $\alpha$ -HBCDD. The elimination half-life for HBCDDs (expressed as the sum of the  $\alpha$ ,  $\beta$  and  $\gamma$  isomers) in humans was estimated to be 64 days (range 23-219 days).

8. Data concerning the toxicity of individual stereoisomers were available only from an *in vitro* cytotoxicity study (Zhang *et al.*, 2008). This indicated that that the (+)-isomers were generally more toxic than the (-)-isomers in the order  $(+)\alpha = (+)\gamma > (+)\beta > (-)\gamma > (-)\alpha = (-)\beta$ . EFSA concluded that the relevance of these findings to the *in vivo* toxicity of HBCDDs was unclear, but that in general they appeared to support the low acute toxicity of the compounds tested.

9. The main targets for HBCDD toxicity in experimental animals were the liver, thyroid hormone homeostasis, and the immune, reproductive and nervous systems. The two available epidemiological studies did not show any association between levels of HBCDDs in blood and bone mineral density in elderly women, or between HBCDDs in human milk and neonatal blood levels of thyroid stimulating hormone (TSH). Like COT, EFSA concluded that because of limitations and uncertainties in the database, the derivation of a TDI was not appropriate, and instead an MOE approach was adopted (EFSA 2011). Since all *in vivo* toxicity studies had been carried out with technical HBCDD mixtures, risk assessments for individual stereoisomers were not possible.

10. EFSA noted that most studies showed effects on the regulation of thyroid hormones, and that the investigation showing effects at the lowest doses was a 28-day study of HBCDDs in rats by van der Ven *et al* (2006). The most sensitive effect was increased relative thyroid weight in female rats. There was no clear dose-response relationship, but a lower 95% confidence limit for a benchmark response of 10 % (BMDL<sub>10</sub>) of 1.6 mg/kg bw per day could be derived. Changes in blood levels of total T4, immunostaining for TSH in the pituitary, and pituitary weight were observed at higher doses, and were restricted to females, which was consistent with a finding of higher liver concentrations of HBCDDs in females than in males. EFSA noted that extrapolation of effects on thyroid hormone homeostasis observed in rodents to humans was complicated by species differences in transport systems and feedback regulation. There were indications that HBCDDs might act via mechanisms involving the constitutive androstane receptor (CAR) and pregnane X receptor. EFSA concluded that, because thyroid hormone insufficiency could lead to neurodevelopmental effects, both in experimental animals and in humans, the rodent data concerning effects of HBCDDs on thyroid hormone levels and signalling might be of relevance to the assessment of health risks in humans.

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

11. EFSA (2011) identified neurodevelopmental effects as the critical end-point and derived a BMDL<sub>10</sub> from a study by Eriksson *et al.* (2006). Eriksson *et al.* administered a single oral gavage dose of HBCDDs ( $\alpha$ -,  $\beta$ - and  $\gamma$ -HBCDD in relative proportions of 3 %, 8 % and 89 %) at either 0.9 or 13.5 mg/kg bw to mouse pups at the age of 10 days, which is the peak time of brain growth in mice. At 3 months of age the mice were tested for effects on locomotion and memory. The mice treated with HBCDDs at the higher dose initially scored lower than controls and low dose animals in the tests of locomotion, but maintained their level of activity such that after 40 minutes they were significantly more active than the other two groups ( $p < 0.01$ ). The higher dose group also took significantly longer than the other groups to complete a swim maze test ( $p < 0.05$ ), suggesting that spatial learning was impaired. EFSA modelled the dose-response data from this study to derive a BMDL<sub>10</sub> of 0.93 mg/kg bw. They noted limitations of the single-administration protocol, but concluded that use of this BMDL<sub>10</sub> in the risk assessment was justified because the observed effects occurred at the lowest doses that had been associated with developmental effects on behaviour and covered a relevant neurodevelopmental period in the experimental animals.

12. The much slower rate of elimination in humans than in rodents led EFSA to take differing toxicokinetics into account by estimating the daily human intake which, after attainment of steady state, would produce the same body burden as might occur in rodents following a single dose by gavage at the BMDL<sub>10</sub> (assuming 85% uptake from the gut). Using the longest estimated human half-life of 219 days, this intake was calculated to be 3  $\mu$ g/kg bw/day, which was then used as the reference point in the MOE approach.

13. EFSA also noted that effects on bone mineral density were observed in a one generation reproductive study in rats, with a BMDL<sub>10</sub> of 0.056 mg/kg bw (van der Ven *et al.*, 2009), but that the ratio between the BMDL<sub>10</sub> and the benchmark dose upper confidence limit (BMDU<sub>10</sub>) indicated “a large variation in the dose response data”<sup>2</sup>. EFSA therefore concluded that the BMDL<sub>10</sub> for effects on bone mineral density should not be used as the reference point for the MOE, and that further studies were needed to confirm the effect.

## **New toxicological and epidemiological data**

### ***Toxicokinetics***

14. Toxicokinetic data published since EFSA (2011) indicate that  $\geq 85\%$  of an oral dose of  $\beta$ -HBCDD was absorbed in mice, with a T<sub>max</sub> (time to peak serum concentration) of 3 hours (Sanders *et al.*, 2013). Of this, absorbed dose, approximately 90% was excreted in urine and faeces within 24h, primarily as  $\beta$ -HBCDD-derived metabolites, but 9% was excreted in the faeces as  $\gamma$ -HBCDD. An *in vitro* human colon model yielded similar results for a mixture of isomers ( $\alpha$  92%,  $\beta$  80% and  $\gamma$  72%) from domestic dust (Abdallah *et al.*, 2012). Other studies have confirmed the widespread distribution of HBCDDs in the body, with metabolism by debromination and hydroxylation. Hakk *et al.* (2012) dosed female mice with <sup>14</sup>C-

---

<sup>2</sup> COT noted that it would be more accurate to say that this reflects large statistical uncertainty

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

labelled  $\alpha$ - or  $\gamma$ - HBCDD and identified hydroxylated debrominated metabolites from each isomer in urine, faeces and tissue. Malarvannan *et al.* (2013) found predominantly  $\alpha$ -HBCDD in human visceral and subcutaneous fat from obese individuals. In Canadian studies, low but measurable concentrations of HBCDDs were reported in human sera (geometric mean 0.851  $\mu\text{g}/\text{kg}$  lipid, Rawn *et al.*, 2014a), placenta (median 48  $\mu\text{g}/\text{kg}$  lipid) and fetal liver (median 29  $\mu\text{g}/\text{kg}$  lipid) (Rawn *et al.*, 2014b).

## **Toxicity**

15. Newly reported studies of toxicity have used mixtures of HBCDDs purchased from bulk chemicals companies, with unspecified isomeric proportions.

16. Following exposure of pregnant dams to >1000 – 10 000ppm HBCDDs in the diet, changes were observed in neuronal migration in the dentate gyrus of rat pups (Saegusa *et al.*, 2012), and in rat fetal glial cell development (Fujimoto *et al.*, 2013), possibly resulting from effects on the thyroid gland. Rasinger *et al.* (2014) fed juvenile BALB/c mice a diet containing 1300 ppm HBCDDs that resulted in a dose of 200 mg/kg bw per day for 28 days. HBCDD induced 90 genes in the brain and the authors hypothesised that the overall effect would be alterations in calcium and zinc homeostasis leading to excitotoxicity. Dietary administration of HBCDDs to mice at 199 mg/kg bw/day for 28 days resulted in increased liver weight and fat content (Maranghi *et al.*, 2013). Sensitivity to this effect appeared to be increased when dietary fat content was higher, leading to significant increases in liver- and body-weight following weekly bolus gavage doses of 35 or 700  $\mu\text{g}/\text{kg}/\text{week}$  (Yanagisawa *et al.*, 2014).

17. Recent *in vitro* studies have provided information on possible modes of action for HBCDDs, including oestrogenic activity (Dorosh *et al.*, 2011), generation of reactive oxygen species (An *et al.* 2014) and inhibition of calcium transport in the smooth endoplasmic reticulum (Al-Mousa & Michaelangeli, 2014). HBCDDs reduced splenocyte viability but enhanced the differentiation of bone marrow cells into dendritic cells (Koike *et al.*, 2013). HBCDDs inhibited cAMP production and the expression of several cAMP-dependent steroidogenesis genes in rat Leydig cells, but increased basal steroidogenesis (Fa *et al.*, 2013). HBCDDs potentiated FSH-stimulated EGF receptor phosphorylation and activated ERK1/2 and PKB (AKT), but decreased FSH-induced luteinizing hormone receptor expression (Fa *et al.*, 2014). Both An *et al.* (2014) and Fa *et al.* (2013) found that HBCDDs reduced mitochondrial membrane potential in cells *in vitro*. All of these effects were observed at HBCDD concentrations in the range of 15 nM to 40  $\mu\text{M}$ . The lowest concentration at which HBCDDs were seen to have an effect *in vitro* was 0.1nM, which produced suppression of thyroid hormone (TH)-stimulated transcription and dendrite arborisation of new-born rat Purkinje cells (Ibhazehiebo *et al.*, 2011a). Ibhazehiebo *et al.* (2011b) also observed inhibition of TH-induced neurite extension of cerebellar granule cells by 0.1nM HBCDDs, possibly through reduced production of bone-derived neurotrophic factor, which promotes granule cell development.

### ***Epidemiological studies***

18. Kim & Oh (2014) reported a statistically significant ( $p < 0.05$ ) negative correlation between serum levels of HBCDDs and the level of triiodothyronine (T3) in the mothers of children with congenital hypothyroidism. The authors concluded that although the findings were suggestive of effects on human thyroid function, the small number of subjects tested (26 mother-infant pairs) meant that a larger study would be needed to confirm the results.

19. The total HBCDD concentration in house dust has been correlated ( $p = 0.004$ , Spearman's  $r = 0.46$ ,  $n = 28$ ) with decreased sex hormone binding globulin and increased free androgen index in men (Johnson *et al.*, 2013), but exposures were not estimated. Meijer *et al.* (2012) found HBCDDs at  $0.7 \mu\text{g/kg}$  fat in the serum of 34 women at the 35<sup>th</sup> week of pregnancy, but no correlation with the testicular volume or penile length of their infants postnatally.

### **COT evaluation**

20. COT noted that the female specificity of effects in the 28-day study of technical HBCDD ( $\alpha$  10.3%,  $\beta$  8.7%,  $\gamma$  81.0%) in rats by van der Ven *et al.* (2006) contrasted with the findings of Chengelis *et al.* (2001), who reported similar effects in both sexes, and that the effects of HBCDDs on the thyroid hormone axis were likely to be secondary to increased hepatic clearance of T4 via glucuronidation.

21. The study by Maranghi *et al.* (2013) suggested that obese individuals might be more sensitive to HBCDDs than leaner people, but did not provide a suitable basis from which to derive a reference point for the characterisation of risk.

22. The new *in vitro* toxicity data suggest that technical mixtures of HBCDDs have a range of effects on different cell types, but give little insight into the toxic effects observed *in vivo*. Regarding the epidemiological studies, COT noted limitations in the reporting and agreed that further studies would be needed to verify the findings that had been reported.

23. Overall, the new data did not demonstrate a mode of action for HBCDDs or provide an improved basis for extrapolation of experimental animal data to the human situation. Thus, they did not offer an alternative approach to the reference point identified by EFSA from the study by Eriksson *et al.* (2006), which remained the best available starting point for risk assessment.

### **Sources of exposure to HBCDDs**

24. HBCDDs have been found in air, indoor dust, soil, food and breast milk. No consistent temporal trends in concentrations have been apparent (Law *et al.*, 2014; Dietz *et al.*, 2013).

### ***Environmental occurrence of HBCDDs***

*Air, dust and soil*

25. Abdallah *et al.* (2008) found a mean concentration of 250 pg total  $\alpha+\beta+\gamma$  HBCDD/m<sup>3</sup> (range 67 – 1300 pg/m<sup>3</sup>) in indoor air from 45 homes in Birmingham UK. It is unclear whether these concentrations included HBCDDs in suspended particles, or only in the gaseous phase. The mean concentration of HBCDDs in indoor dust in the same study was 8300  $\mu\text{g}/\text{kg}$  (range 140 – 140000  $\mu\text{g}/\text{kg}$ ). Both air and dust showed isomeric proportions that had shifted from those in technical HBCDD ( $\alpha:\beta:\gamma$  3:8:89), air containing 22%  $\alpha$ : 11%  $\beta$ : 65%  $\gamma$  and dust containing 33%  $\alpha$ : 11%  $\beta$ : 56%  $\gamma$ . Table 1 shows measurements of HBCDDs in dust from UK houses and cars.

Table 1. HBCDDs in dust from houses and cars in the UK

Sampling date where given	Environment	Total $\alpha+\beta+\gamma$ HBCDD concentration ( $\mu\text{g}/\text{kg}$ )	Reference
March – December 2007	House (n = 21)	228 – 140774 (range) 10021 (mean)	Abdallah <i>et al.</i> , 2009
	Car (n=12)	194 – 55822 (range) 18488 (mean)	
	House (n = 45)	140 – 140000 (range) 8300 (mean)	Abdallah <i>et al.</i> , 2008
	House (5 samples from each of 3 houses)	170 – 19000 (range)	Harrad <i>et al.</i> , 2009
2009	Car (n = 14)	9200 (median)	Harrad and Abdallah., 2011

26. A study investigating spatial and temporal enantiomeric shifts in HBCDDs in household dust revealed a rapid photolytically-mediated shift from  $\gamma$ -HBCDD to  $\alpha$ -HBCDD that was complete after one week of exposure to daylight, and a slower degradative loss of HBCDDs through elimination of HBr. With exposure to light, the decay in total HBCDD concentration was faster than in light-shielded samples ( $t_{1/2}$  =12 weeks and 24 weeks respectively). Spatial variation within sampled rooms was substantial, and in one room correlated negatively with distance from a television that was identified as the source of HBCDDs. The total  $\alpha+\beta+\gamma$  HBCDD concentration in dust was 540,000  $\mu\text{g}/\text{kg}$  inside the TV, 24,000  $\mu\text{g}/\text{kg}$  at 1 metre, and fell to 5,700  $\mu\text{g}/\text{kg}$  at 4 metres. In one room, a significant negative correlation was observed between concentrations of total HBCDDs and dust loading (g dust/m<sup>2</sup> floor), implying that "dilution" occurred at higher dust loadings (Harrad *et al.*, 2009).

27. Data have been reported on levels of HBCDDs in soil at polluted industrial sites in China and other Far Eastern countries, but no information is available about soil levels in the UK.



## **Dietary occurrence of HBCDD**

### *Breast milk*

28. A study conducted in Birmingham, UK, found HBCDDs in 34 samples of human milk (collection period unspecified). The mean total concentration of  $\alpha+\beta+\gamma$  HBCDDs was 5.95 ng/kg lipid weight, which is equivalent to 208 pg/kg whole weight (assuming 3.5% fat content). The  $\alpha$ -isomer accounted for 62-95% of the measured HBCDDs while  $\beta$ - and  $\gamma$ -HBCDD made up 2-18% and 3-33% respectively (see Table 2). Enantioselective enrichment of (-)- $\alpha$ -HBCDD (average enantiomer fraction = 0.29) was observed, indicating possible differences between enantiomers in absorption, metabolism and/or excretion (Abdallah & Harrad, 2011). The measured concentrations were in broad agreement with findings from a study in Ireland that measured HBCDDs and other halogenated flame retardants in breast milk, and found a mean summed concentration of HBCDD enantiomers of 3.52 ng/kg lipid weight, with  $\alpha$ -HBCDD making up over 70% of the total (Pratt *et al.*, 2013).

Table 2. HBCDD in 34 samples of breast milk from the UK.

Reference	Isomer	HBCDD concentrations in breast milk (pg/kg whole weight) <sup>a</sup>			
		Arithmetic Mean	Minimum	Median	Maximum
Abdallah & Harrad 2011	$\alpha$	172	26.3	111	690
	$\beta$	11.2	2.80	10.5	26.3
	$\gamma$	25.6	4.55	19.6	80.2
	Sum	208	36.4	134	783

<sup>a</sup> Data converted to whole milk basis from fat weight basis assuming breast milk contains 3.5% fat.  
Sum = sum of  $\alpha + \beta + \gamma$

### *Infant formula and complementary foods*

29. No measurements of HBCDDs in infant formula or commercially produced infant foods are available from the UK.

30. In data submitted to EFSA by EU countries, HBCDDs were not found in 3 samples of infant formula (limit of detection not stated in the EFSA report) but could be measured in 38% of 13 samples described as “Ready-to-eat meal for infants and small children”. The lower and upper bounds<sup>3</sup> (LB and UB) of the mean for these 16 samples were 0.01 and 0.03  $\mu\text{g}/\text{kg}$  respectively EFSA (2011)

### *Food*

<sup>3</sup> The lower bound for the mean was calculated with the assumption that unmeasurable concentrations were zero, and the upper bound with the assumption that they were at the limit of detection.

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

31. The most recent measurements of HBCDDs in foods sampled in the UK are for the composite food groups of the 2012 Total Diet Study (TDS) (Fernandes *et al.*, 2012). The three major diastereomers were each measured individually. Levels were mostly below the limits of detection, as shown in Table 3.

Table 3. Concentrations of HBCDD isomers in food expressed on a whole weight basis

Food group	Mean concentration of HBCDD isomer in food item ( $\mu\text{g}/\text{kg}$ )		
	$\alpha$ -HBCDD	$\beta$ -HBCDD	$\gamma$ -HBCDD
Bread	0.03	<0.02	0.03
Cereals	0.03	<0.02	<0.02
Carcase meat	0.25	<0.01	<0.01
Offal	0.03	<0.01	<0.01
Meat products	0.1	0.02	<0.02
Poultry	<0.01	<0.01	<0.01
Fish	0.08	<0.01	<0.01
Fats & oils	0.16	<0.03	<0.05
Eggs	<0.01	<0.01	<0.01
Sugar and Preserves	<0.02	<0.01	<0.02
Green vegetables	0.01	<0.01	<0.01
Potatoes	<0.01	<0.01	<0.01
Other vegetables	<0.01	<0.01	<0.01
Canned Vegetables	<0.01	<0.01	<0.01
Fresh Fruit	<0.01	<0.01	<0.01
Fruit Products	0.04	<0.02	<0.03
Milk	<0.01	<0.01	<0.01
Dairy Products	0.03	<0.02	<0.02
Nuts	<0.06	<0.10	0.06

Values prefixed by "<" were below limits of quantification

32. EFSA (2011) reported that the LB and UB of the mean for the sum of the three major HBCDD stereoisomers in ten fish oil samples were 1.21 and 1.86  $\mu\text{g}/\text{kg}$  fat, with a high proportion of the total being  $\alpha$ -HBCDD. The  $\alpha$  isomer was detected more frequently than the  $\beta$  or  $\gamma$ . Three samples were described as fish oil bottled and seven as fish oil in capsules. The liquid fish oil contained up to ten times higher concentrations of  $\alpha$ -HBCDD than the capsules (LB and UB of the mean 2.83 and 2.99  $\mu\text{g}/\text{kg}$  respectively).

### **Drinking Water**

33. No measurements of HBCDDs in drinking water in the UK are available.

### **Exposure to HBCDDs**

34. The assessments presented here are for external exposures from air, dust and the diet. Data on bodyweight are from the UK Dietary and Nutrition Survey of Infants and Young Children (DNSIYC, DH, 2013), with average bodyweights of 7.8, 8.7 and 9.6 kg for infants aged >4 – 6.0, >6.0 – 9.0 and >9.0 – 12.0 months

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

respectively. Since DNSIYC did not include infants younger than 4 months, in this statement a value of 5.9 kg for infants ages 0 – 3 months from an earlier survey (DH, 1994) is assumed for infants aged 0 – 4 months.

### **Environmental Exposure to HBCDDs**

#### *Air and Dust*

35. Potential exposures of UK infants to HBCDDs in air, assuming a ventilation rate of 3 m<sup>3</sup>/day (US EPA, 1989), and the mean reported occurrence of 250 pg/m<sup>3</sup> for the sum of HBCDDs in domestic air (paragraph 25), are 0.127, 0.096, 0.086 and 0.078 ng/kg bw/day at ages 0-4, 4-6, 6-9 and 9-12 months respectively

36. Assuming daily ingestion of 100 mg of dust (WHO, 2007), and the values for HBCDD in house dust from Abdallah *et al.* (2009) in Table 1, infants aged 9-12 months (who are more likely to come into contact with floors and other surfaces than those in younger age groups) would be exposed on average to 104 ng/kg bw/day HBCDDs, with a range of 2.4 – 1466 ng/kg bw/day.

### **Dietary exposure to HBCDDs**

#### *Breast milk*

37. Table 4 shows estimated exposures of exclusively breast-fed infants based on the median and maximum concentrations in the study by Abdallah and Harrad (2011), and assuming average (800 mL) or high-level (1200 mL) daily consumption of breast milk.

Table 4. Estimated exposures of UK infants to HBCDDs from exclusive breastfeeding.

Isomer	Exposure pg/kg bw/day							
	Average consumer 800 mL/day				High consumer 1200 mL/day			
	0 - 4 months		>4 – 6 months		0 - 4 months		>4 – 6 months	
	Median	Max	Median	Max	Median	Max	Median	Max
$\alpha$	15.1	93.6	11.4	70.8	22.6	140	17.1	106
$\beta$	1.42	3.57	1.08	2.70	2.14	5.35	1.62	4.05
$\gamma$	2.66	10.9	2.01	8.23	3.99	16.3	3.02	12.3
Sum	18.2	106	13.7	80.3	27.3	159	20.6	120

Exposure values calculated from occurrence data from Abdallah and Harrad, 2011.

Sum = sum of  $\alpha$  +  $\beta$  +  $\gamma$

#### *Food*

38. No data are available on concentrations of HBCDDs in infant formula and commercially-produced infant food in the UK. EFSA (2011) did not estimate infants'

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

exposure to HBCDDs from infant formula and “ready-to-eat meal for infants and small children” because the available data were too limited.

39. Table 5 summarises upper bound mean and high-level estimates<sup>4</sup> of infant dietary exposure to HBCDDs, calculated using measurements for the 19 composite food groups analysed in the 2012 TDS (see Table 3) in combination with data on consumption of those foods from DNSIYC (DH, 2013). Since HBCDDs were not detected in most of the food groups, it is possible that the upper bound estimates are substantially higher than actual exposures. Estimates for individual food items are presented in Annex 1.

Table 5 Estimated dietary exposure of infants to HBCDDs in food

HBCDD isomer	Upper bound dietary exposure to HBCDD isomers (ng/kg bw/day)					
	4 – 6 months		6 – 9 months		9 – 12 months	
	Mean	P97.5	Mean	P97.5	mean	P97.5
$\alpha$	1.39	4.41	1.62	4.50	1.74	3.70
$\beta$	0.92	2.94	1.00	2.85	1.02	2.25
$\gamma$	0.93	2.94	1.01	2.85	1.05	2.29
Sum	3.24	9.29	3.63	10.2	3.81	8.24

P97.5 = 97.5<sup>th</sup> percentile

Sum = sum of  $\alpha$  +  $\beta$  +  $\gamma$

40. Although dietary supplements like cod liver oil are not recommended for children under 3 years of age, there were four recorded cases in the DNSIYC in which infants aged 4 to 12 months were given daily doses of 9 to 62 mg fish oil /kg bw, either by spoon or as capsules. The small number of consumers in DNSIYC and the incompleteness of the recorded data on consumption mean that there are large uncertainties in performing a risk assessment for HBCDDs in fish oil. However, assuming the highest UB concentration of HBCDDs reported by EFSA, 62 mg fish oil /kg bw would lead to an exposure of 0.12 ng HBCDDs /kg bw.

### Risk Characterisation for HBCDDs

41. MOEs were calculated as the ratio of the reference point of 3  $\mu\text{g}/\text{kg bw}/\text{day}$ , derived from a study on a technical mixture of HBCDDs (Eriksson et al., 2006), to estimates of exposures to HBCDDs. For exposure of infants from air, MOEs based on the mean reported airborne concentration of HBCDDs, were in the range 5280 – 103400 according to age group. For dust, the MOEs based on the range of reported HBCDD concentrations were 2.0 – 1260.

<sup>4</sup> These estimates all assume that unmeasured concentrations were at the limit of detection. Mean values represent the average intake with this assumption, and high-level values the 97.5<sup>th</sup> centile of the distribution of intakes.

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

42. Table 6 shows that the MOEs for exposure to HBCDDs in exclusively breastfed infants, calculated from the maximum reported concentration of HBCDDs in breast milk, are 19,000 or higher.

Table 6. MOEs for exposure to HBCDDs in exclusively breastfed infants in the UK.

Isomer	MOE for HBCDDs in breast milk			
	Average consumer 800 mL/day		High consumer 1200 mL/day	
	Age 0 - 4 months	Age >4 – 6 months	Age 0 - 4 months	Age >4 – 6 months
$\alpha$	32,000	42,000	21,000	28,000
$\beta$	830,000	1,100,000	570,000	750,000
$\gamma$	280,000	370,000	180,000	240,000
Sum	28,000	37,000	19,000	25,000

Sum = sum of  $\alpha$  +  $\beta$  +  $\gamma$

43. Table 7 shows MOEs for infant exposures to HBCDDs via the diet. The MOEs for the sum of  $\alpha$ -,  $\beta$ - and  $\gamma$ -HBCDDs are in the region of 300 or higher.

Table 7. MOEs for dietary exposure of infants to HBCDD

HBCDD isomer	MOEs for upper bound dietary exposure to HBCDD isomers					
	4 – 6 months		6 – 9 months		9 – 12 months	
	Mean	P97.5	Mean	P97.5	mean	P97.5
$\alpha$	2200	680	1900	670	1700	810
$\beta$	3300	1000	3000	1100	2900	1300
$\gamma$	3200	1000	3000	1100	2900	1300
Sum	930	320	830	290	790	364

P97.5 = 97.5<sup>th</sup> percentile

Sum = sum of  $\alpha$  +  $\beta$  +  $\gamma$

44. For fish oil, the MOE for the highest level of consumption is 25000.

45. EFSA (2011) noted that usually an MOE of 100 is considered to provide adequate reassurance that there is no health concern regarding the toxic effect on which it is based. A margin of this magnitude covers uncertainties regarding toxicokinetic and toxicodynamic differences between experimental animals and humans (factor 4 x 2.5 = 10), and within the human population (factor 3.2 x 3.2 = 10). This breakdown of the uncertainty factors is consistent with the COT Report on Variability and Uncertainty in Toxicology (COT, 2007)<sup>[1]</sup>. Since for HBCDDs the MOE approach was based on a body burden comparison between animals and humans, using the higher end of the reported range for elimination half-life in humans, EFSA (2011) considered that the potential for kinetic differences between species had

<sup>[1]</sup> <http://cot.food.gov.uk/cotreports/cotwgreports/cotwgvut>

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

been taken into account. Similarly, by focusing on the body burden associated with a BMDL<sub>10</sub> for neurobehavioural effects in mice induced during a relevant period for brain development, and applying that body burden to the entire life span in humans, EFSA (2011) took the view that individual differences in susceptibility had been covered. EFSA thus concluded that in their risk assessment for HBCDDs, the calculated MOEs needed to cover inter-species differences in dynamics (factor 2.5) and the uncertainties in the elimination half-life in humans (factor 3.2). This implied that an MOE greater than 8 (2.5 x 3.2) would indicate that there was no concern for health

46. The COT agreed that inter-species differences in toxicokinetics were accounted for by the body burden approach, and that the use of data relating to a critical period of development reduced uncertainties in the risk assessment. However, they considered that MOEs should be rather higher than 8 to provide reasonable assurance of safety.

47. From the above evaluation, the MOE values for HCDDs in air, breast milk and food are all substantially in excess of 8, but for dust the highest estimated exposure gives an MOE below this value.

## Uncertainties

48. The toxicity study used by EFSA to derive the reference point for MOEs involved a single gavage administration to neonatal mice. There is uncertainty about the relevance of this study to risk assessment for longer term repeated exposures in humans. However, since the neurobehavioural effects were observed at lower doses than in other studies and covered a relevant neurodevelopmental period in experimental animals, they cannot be discounted. The long half-lives of HBCDDs mean that after a single administration, systemic exposure would continue over a prolonged period. Furthermore, it may be reasoned that when the body burden following single administration matches that in steady state from repeated exposures, most tissue concentrations are likely to be higher as there will have been limited redistribution to adipose tissue. This would tend to make the derivation of reference points from a single dose study conservative.

49. Conversely, if adverse effects depended on the exposure of tissues at a critical time point which did not coincide exactly with that at which the maximum level was reached following single administration, it is possible that the single dose studies could overestimate the body burden needed to produce toxicity.

50. HBCDDs have been used as technical mixtures, and the profile of isomers now present in food and the environment differs from that in the original mixtures. There is uncertainty about the exact profile of exposure to HBCDDs, and the effects of this combined exposure. This has been addressed to some extent by calculating MOEs for exposure to the sum of measured HBCDDs. However, the possibility cannot be ruled out that toxic potency varies according to the relative concentrations of different isomers.

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

51. In addition, no data were available on levels of HBCDDs in infant formula or commercially produced infant foods in the UK

## **Conclusions**

52. HBCDDs have been produced as technical mixtures containing 3 major HBCDD isomers, and there are only limited data on their individual toxicological properties. Tests of toxicity conducted with technical mixtures are of limited relevance to the profile of HBCDDs that occurs in the environment and in food, owing to differing persistence of individual isomers.

53. In animal studies, the main targets of HBCDD toxicity are the liver, thyroid hormone homeostasis, and the reproductive and nervous systems. Epidemiological data on possible adverse effects in human populations are inconsistent, and cannot be used as a basis for quantitative risk assessment.

54. The available data are insufficient to establish Tolerable Daily Intakes for HBCDDs. Therefore the COT adopted a Margin of Exposure (MOE) approach to risk assessment, in which estimated exposures of infants to HBCDDs were compared to a reference point derived from toxicity studies.

55. The reference point was determined from a study in which neonatal mice were given a technical mixture of HBCDDs by a single gavage administration, and behavioural changes were observed in adulthood. The Committee had some reservations about this study, but in the context of a limited database, concluded that it provided a reasonable basis for risk assessment.

56. In the absence of adequate toxicity data for individual congeners, the COT compared exposures to HBCDDs with this reference point. Overall the analysis indicated that estimated exposures via breast milk and food are not a cause for concern, but that high levels found in some samples of domestic dust are. Further dust sampling should be carried out to obtain a more reliable assessment of the distribution of potential exposures through ingestion of dust, and especially to establish whether levels begin to fall now that production and new usage of HBCDDs has largely ceased. New studies on the levels of HBCDDs in infant formula and baby food would also be useful, but are of lower priority

**Secretariat**  
**January 2015**

## References

- Abdallah MA, and Harrad S (2009). Personal exposure to HBCDDs and its degradation products via ingestion of indoor dust. *Environ Int.* **35(6)**: 870-6. doi: 10.1016/j.envint.2009.03.002. Epub 2009 Apr 3.
- Abdallah MA, and Harrad S. (2011). Tetrabromobisphenol-A, hexabromocyclododecane and its degradation products in UK human milk: relationship to external exposure *Environ Int.* **37(2)**:443-8. doi: 10.1016/j.envint.2010.11.008.
- Abdallah MA, Harrad S, and Covaci A (2008). Hexabromocyclododecanes and tetrabromobisphenol-A in indoor air and dust in Birmingham, U.K: implications for human exposure. *Environ Sci Technol.* **42(18)**:6855-61.
- Abdallah MAE, Tilston E, Harrad S, and Collins, C (2012). In vitro assessment of the bioaccessibility of brominated flame retardants in indoor dust using a colon extended model of the human gastrointestinal tract. *Journal Of Environmental Monitoring.* **14(12)**: 3276-3283. doi: 10.1039/c2em30690e
- Al-Mousa F, and Michelangeli F (2014). The sarcoplasmic-endoplasmic reticulum Ca(2+)-ATPase (SERCA) is the likely molecular target for the acute toxicity of the brominated flame retardant hexabromocyclododecane (HBCDD). *Chem Biol Interact.* **207**:1-6. doi: 10.1016/j.cbi.2013.10.021.
- An J, Chen C, Wang X, Zhong Y, Zhang X, Yu Y, and Yu Z (2014). Oligomeric proanthocyanidins alleviate hexabromocyclododecane-induced cytotoxicity in HepG2 cells through regulation on ROS formation and mitochondrial pathway. *Toxicol In Vitro.* **28(2)**:319-26. doi: 10.1016/j.tiv.2013.11.009.
- An J, Wang X, Guo P, Zhong Y, Zhang X, and Yu Z (2014). Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase B pathway. *Toxicol Lett.* pii: S0378-4274(14)00275-6. doi: 10.1016/j.toxlet.2014.06.025.
- Baldwin W S, Curtis S W, Cauthen C A. Risinger J I, Korach K S and Barrett J C (1998) BG-1 ovarian cell line: An alternative model for examining estrogen-dependent growth in vitro. *In Vitro Cellular & Developmental Biology – Animal* **34 (8)** 649-654.
- Chengelis CP. A 90-day oral (gavage) toxicity study of HBCD in rats. 2001; WIL-186012, pp 1527. Wil Reserach Laboratories, Inc., Ashland, Ohio, USA.
- Dietz R, Riget FF, Sonne C, Born EW, Bechshoft T, McKinney MA, Drimmie RJ, Muir DCG and Letcher RJ (2013). Three decades (1983 – 2010) of contaminant trends in East Greenland polar bears (*Ursus maritimus*). Part 2: Brominated flame retardants. *Environ, Int.* **59**:494 – 500.



This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

Dorosh A, Ded L, Elzeinova F and Peknicova J (2011). Assessing Oestrogenic Effects of Brominated Flame Retardants Hexabromocyclododecane and Tetrabromobisphenol A on MCF-7 Cells. *J Folia Biologica* **57(1)**: 35-39.

Eriksson P, Fischer C, Wallin M, Jakobsson E and Fredriksson A. (2006) Impaired behaviour, learning and memory, in adult mice neonatally exposed to hexabromocyclododecane (HBCDD). *Environmental Toxicology and Pharmacology*, 21, 317-322

EU RAR (2008) <http://echa.europa.eu/documents/10162/661bff17-dc0a-4475-9758-40bdd6198f82>

Fa S, Pogrmic-Majkic K, Dakic V, Kaisarevic S, Hrubik J, Andric N, Stojilkovic SS, and Kovacevic R (2013). Acute effects of hexabromocyclododecane on Leydig cell cyclic nucleotide signaling and steroidogenesis in vitro. *Toxicol Lett.* **218(1)**: 81-90. doi: 10.1016/j.toxlet.2013.01.009.

Fa S, Samardzija D, Odzic L, Pogrmic-Majkic K, Kaisarevic S, Kovacevic R, and Andric N (2014). Hexabromocyclododecane facilitates FSH activation of ERK1/2 and AKT through epidermal growth factor receptor in rat granulosa cells. *Archives of Toxicology* **88(2)**: 345-354 doi: 10.1007/s00204-013-1133-2.

Fernandes A, Rose M, Smith F and Holland M (2012).. Organic Environmental Contaminants in the 2012 Total Diet Study Samples Report to the Food Standards Agency. Available at: [http://www.foodbase.org.uk/admintools/reportdocuments/848-1-1561\\_FS241031\\_TDS\\_2012\\_final.pdf](http://www.foodbase.org.uk/admintools/reportdocuments/848-1-1561_FS241031_TDS_2012_final.pdf)

Fujimoto H, Woo GH, Morita R, Itahashi M, Akane H, Nishikawa A, and Shibutani M.J (2013). Increased cellular distribution of vimentin and ret in the cingulum of rat offspring after developmental exposure to decabromodiphenyl ether or 1,2,5,6,9,10-hexabromocyclododecane. *Toxicol Pathol.* **26(2)**: 119-29. doi: 10.1293/tox.26.119.

Hakk H, Szabo DT, Huwe J, Diliberto J, and Birnbaum LS (2012). Novel and distinct metabolites identified following a single oral dose of  $\alpha$ - or  $\gamma$ -hexabromocyclododecane in mice. *Environ Sci Technol.* **18;46(24)**: 13494-503. doi: 10.1021/es303209g.

Harrad S, Abdallah MAE, and Covaci A (2009a). Causes of variability in concentrations and diastereomer patterns of hexabromocyclododecanes in indoor dust. *Environment International* **35(3)**: 573-579 doi: 10.1016/j.envint.2008.10.005

Harrad S, Abdallah M, Rose NL, Turner SD, Davidson TA. 2009b. Current-use brominated flame retardants in water, sediment, and fish from English lakes. *Environ Sci Technol* 43(24):9077–9083

Harrad S, and Abdallah MA (2008). Calibration of two passive air sampler configurations for monitoring concentrations of hexabromocyclododecanes in indoor air. *J Environ Monit.* **10(4)**: 527-31. doi: 10.1039/b719638e.

Harrad S, and Abdallah MAE (2011). Brominated flame retardants in dust from UK cars - Within-vehicle spatial variability, evidence for degradation and exposure

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

implications *Chemosphere*. **82(9)**: 1240-1245 doi:  
10.1016/j.chemosphere.2010.12.038.

Ibhazehiebo K, Iwasaki T, Shimokawa N, and Koibuchi, N (2011a). 1,2,5,6,9,10- $\alpha$  Hexabromocyclododecane (HBCDD) Impairs Thyroid Hormone-Induced Dendrite Arborization of Purkinje Cells and Suppresses Thyroid Hormone Receptor-Mediated Transcription. *Cerebellum* **10(1)**: 22-31 doi: 10.1007/s12311-010-0218-1.

Ibhazehiebo K, Iwasaki T, Xu M, Shimokawa N, and Koibuchi N (2011b). Brain-derived neurotrophic factor (BDNF) ameliorates the suppression of thyroid hormone-induced granule cell neurite extension by hexabromocyclododecane (HBCDD). *Neuroscience Letters* **493(1-2)**: 1-7 doi: 10.1016/j.neulet.2011.01.062.

Johnson PI, Stapleton HM, Mukherjee B, Hauser R, and Meeker JD (2013). Associations between brominated flame retardants in house dust and hormone levels in men. *Sci Total Environ*. **445-446**: 177-84. doi: 10.1016/j.scitotenv.2012.12.017.

Kim U-J and Oh J-E (2014). Tetrabromobisphenol A and hexabromocyclododecane flame retardants in infant – mother paired serum samples and their relationships with thyroid hormones and environmental factors. *Environmental Pollution*. **184**: 193 – 200.

Koike E, Yanagisawa R, Takigami H and Takano H (2013). Brominated flame retardants stimulate mouse immune cells *in vitro*. *J. Appl. Toxicol*. **33**: 1451 – 1459.

Law RJ, Covaci A, Harrad S, Herzke D, Abdallah MA-E, Fernie K, Toms L-M and Takigami H (2014). Levels and trends of PBDEs and HBCDs in the global environment: Status at the end of 2012. *Environ. Int*. **65**: 147 – 158.

Malarvannan G, Dirinck E, Dirtu AC, Pereira-Fernandes A, Neels H, Jorens PG, Gaal LV, Blust R, and Covaci A (2013). Distribution of persistent organic pollutants in two different fat compartments from obese individuals. *Environ Int*. **55**: 33-42. doi: 10.1016/j.envint.2013.02.012.

Maranghi F, Tassinari R, Moracci G, Altieri I, Rasinger JD, Carroll TS, Hogstrand C, Lundebye AK, and Mantovani A (2013). Dietary exposure of juvenile female mice to polyhalogenated seafood contaminants (HBCDD, BDE-47, PCB-153, TCDD): comparative assessment of effects in potential target tissues. *Food Chem Toxicol*. **56**: 443-9. doi: 10.1016/j.fct.2013.02.056.

Meijer L, Martijn A, Melessen J, Brouwer A, Weiss J, deJong FH and Sauer PJJ (2012). Influence of prenatal organohalogen levels on infant male sexual development: sex hormone levels, testes volume and penile length. *Human Reproduction* **27** (3): 867 – 872.

National Diet and Nutrition Survey: results from Years 1 to 4 (combined) of the rolling programme for 2008 and 2009 to 2011 and 2012. Available online:  
<https://www.gov.uk/government/statistics/national-diet-and-nutrition-survey-results-from-years-1-to-4-combined-of-the-rolling-programme-for-2008-and-2009-to-2011-and-2012>

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

Pratt I, Anderson W, Crowley D, Daly S, Evans R, Fernandes A, Fitzgerald M, Geary M, Keane D, Morrison JJ, Reilly A, and Tlustos C. (2013) Brominated and fluorinated organic pollutants in the breast milk of first-time Irish mothers: is there a relationship to levels in food? Ireland Food Addit Contam Part A Chem Anal Control Expo Risk Assess. **30**(10):1788-98. doi: 10.1080/19440049.2013.822569.

Rasinger JD, Carroll TS, Lundebye AK, and Hogstrand C (2014). Cross-omics gene and protein expression profiling in juvenile female mice highlights disruption of calcium and zinc signalling in the brain following dietary exposure to CB-153, BDE-47, HBCDD or TCDD. *Toxicology* **321C**: 1-12. doi: 10.1016/j.tox.2014.03.006.

Rawn DF, Ryan JJ, Sadler AR, Sun W-F, Weber D, Laffey P, Haines D, macey K and Oostdam JV (2014a). Brominated flame retardant concentrations in sera from Canadian Health Measures Survey (CHMS) from 2007 to 2009. *Environ Int* **63**: 26 - 34

Rawn DF, Gaertner DW, Weber D, Curran IH, Cooke GM, and Goodyer CG (2014b). Hexabromocyclododecane concentrations in Canadian human fetal liver and placental tissues. *Sci. Total Environ.* **468-469**: 622-9. doi: 10.1016/j.scitotenv.2013.08.014.

Saegusa Y, Fujimoto H, Woo GH, Ohishi T, Wang L, Mitsumori K, Nishikawa A, and Shibutani M (2012). Transient aberration of neuronal development in the hippocampal dentate gyrus after developmental exposure to brominated flame retardants in rats. In all cases, a mild hypothyroid effect was seen at high exposures. *Arch Toxicol.* **86**(9): 1431-42. doi: 10.1007/s00204-012-0824-4.

Sanders JM, Knudsen GA, and Birnbaum LS (2013). The Fate of  $\beta$ -Hexabromocyclododecane in Female C57BL/6 Mice. *Toxicological Sciences*, **134**(2): 251-257 doi: 10.1093/toxsci/kft121

STOCKHOLM CONVENTION ON PERSISTENT ORGANIC POLLUTANTS  
STOCKHOLM, 22 MAY 2001. C.N.934.2013.TREATIES-XXVII.15 (Depositary Notification). Available online at:  
<http://chm.pops.int/Implementation/PublicAwareness/NewsFeatures/Clockstartstickin gHBCDamendment/tabid/3547/Default.aspx>

US EPA (U. S. Environmental Protection Agency). (1989). Review of the National ambient air quality standards for lead: exposure analysis methodology and validation. OAQPS staff report. *EPA-450/2-89-011*

van der Ven L, van der Kuil T, Leonards PEG, Slob W, Lilienthal H, Litens H, Herlin M, Hakansson H, Canton RF, van den Berg M, Visser TJ, van Loveren H, Vos J and Piersma AH (2009). Endocrine effects of hexabromocyclododecane (HBCD) in a one-generation reproduction study in Wistar rats. *Toxicology Letters* **185**: 51 - 62.

van der Ven L, Verhoef A, van der Kuil T, Slob W, Leonards PEG, Visser TJ, Hamers T, Herlin M, Hakansson H, Olausson H, Piersma AH and Vos JG (2006) A 28 day oral dose roxicity study enhanced to detect endocrine effects of hexabromocyclododecane in Wistar rats. *Toxicological Sciences* **94**: 281- 292.

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

Yanagisawa R, Koike E, Win-Shwe TT, Yamamoto M, and Takano H (2014). Impaired Lipid and Glucose Homeostasis in Hexabromocyclododecane-Exposed Mice Fed a High-Fat Diet. *Environmental Health Perspectives* **122 (3)**: 277-283 doi: 10.1289/ehp.1307421

Zhang X, Yang F, Xu C, Liu W, Wen S and Xu Y (2008) Cytotoxicity evaluation of three pairs of hexabromocyclododecane (HBCD) enantiomers on Hep G2 cell. *Toxicology in Vitro* **22**: 1520 - 1527

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

## Annex 1

### Upper bound mean dietary exposure of infants to HBCDD isomers in food

Food group	Number of Consumers	4.00 to 5.99 months - HBCD Mean Exposure (ng/kg bw/d)		
		Alpha	Beta	Gamma
Bread	11	0.0230	0.0153	0.0230
Canned vegetables	4	0.0193	0.0193	0.0193
Carcase meat	10	0.2076	0.0083	0.0083
Cereals	59	0.0341	0.0227	0.0227
Dairy products	76	1.6678	1.1118	1.1118
Eggs	2	0.0062	0.0062	0.0062
Fats+oils	14	0.0196	0.0037	0.0061
Fish	6	0.0925	0.0116	0.0116
Fresh fruit	36	0.0376	0.0376	0.0376
Fruit products	29	0.0882	0.0441	0.0661
Green vegetables	33	0.0219	0.0219	0.0219
Meat products	1	0.0744	0.0149	0.0149
Milk	17	0.0308	0.0308	0.0308
Nuts	0	0.0000	0.0000	0.0000
Offal	0	0.0000	0.0000	0.0000
Other vegetables	57	0.0249	0.0249	0.0249
Potatoes	36	0.0232	0.0232	0.0232
Poultry	11	0.0158	0.0158	0.0158
Sugar and preserves <sup>3</sup>	10	0.0045	0.0022	0.0045
<b>Total</b>	<b>102</b>	<b>1.3868</b>	<b>0.9200</b>	<b>0.9274</b>

Food group	Number of Consumers	6.00 to 8.99 months - HBCD Mean Exposure (ng/kg bw/d)		
		Alpha	Beta	Gamma
Bread	242	0.0366	0.0244	0.0366
Canned vegetables	131	0.0167	0.0167	0.0167
Carcase meat	217	0.3727	0.0149	0.0149
Cereals	496	0.0923	0.0615	0.0615
Dairy products	535	1.3122	0.8748	0.8748
Eggs	88	0.0128	0.0128	0.0128
Fats+oils	282	0.0300	0.0056	0.0094
Fish	175	0.0959	0.0120	0.0120
Fresh fruit	385	0.0410	0.0410	0.0410
Fruit products	235	0.0727	0.0363	0.0545
Green vegetables	338	0.0187	0.0187	0.0187
Meat products	93	0.1506	0.0301	0.0301
Milk	270	0.0559	0.0559	0.0559
Nuts	19	0.0129	0.0215	0.0129
Offal	6	0.0123	0.0041	0.0041
Other vegetables	453	0.0347	0.0347	0.0347
Potatoes	389	0.0277	0.0277	0.0277
Poultry	252	0.0111	0.0111	0.0111
Sugar and preserves <sup>3</sup>	172	0.0074	0.0037	0.0074
<b>Total</b>	<b>602</b>	<b>1.6220</b>	<b>0.9965</b>	<b>1.0113</b>

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

Food group	Number of Consumers	9.00 to 11.99 months - HBCD Mean Exposure (ng/kg bw/d)		
		Alpha	Beta	Gamma
Bread	502	0.0561	0.0374	0.0561
Canned vegetables	271	0.0230	0.0230	0.0230
Carcase meat	372	0.3916	0.0157	0.0157
Cereals	656	0.1281	0.0854	0.0854
Dairy products	661	1.0316	0.6877	0.6877
Eggs	207	0.0144	0.0144	0.0144
Fats+oils	456	0.0461	0.0086	0.0144
Fish	305	0.1193	0.0149	0.0149
Fresh fruit	574	0.0511	0.0511	0.0511
Fruit products	322	0.0835	0.0418	0.0626
Green vegetables	436	0.0181	0.0181	0.0181
Meat products	262	0.1475	0.0295	0.0295
Milk	426	0.1050	0.1050	0.1050
Nuts	29	0.0209	0.0349	0.0209
Offal	9	0.0295	0.0098	0.0098
Other vegetables	595	0.0340	0.0340	0.0340
Potatoes	546	0.0344	0.0344	0.0344
Poultry	400	0.0140	0.0140	0.0140
Sugar and preserves <sup>3</sup>	297	0.0091	0.0046	0.0091
<b>Total</b>	<b>684</b>	<b>1.7447</b>	<b>1.0233</b>	<b>1.0515</b>

### Upper bound 97.5th percentile exposure of infants to HBCDD isomers in food

Food group	Number of Consumers	4.00 to 5.99 months - HBCD 97.5 Exposure (ng/kg bw/d)		
		Alpha	Beta	Gamma
Bread	11	0.0488	0.0325	0.0488
Canned vegetables	4	0.0231	0.0231	0.0231
Carcase meat	10	0.5748	0.0230	0.0230
Cereals	59	0.1265	0.0843	0.0843
Dairy products	76	4.4353	2.9569	2.9569
Eggs	2	0.0136	0.0136	0.0136
Fats+oils	14	0.0556	0.0104	0.0174
Fish	6	0.1726	0.0216	0.0216
Fresh fruit	36	0.1362	0.1362	0.1362
Fruit products	29	0.3623	0.1811	0.2717
Green vegetables	33	0.0668	0.0668	0.0668
Meat products	1	0.0744	0.0149	0.0149
Milk	17	0.1256	0.1256	0.1256
Nuts	0	0.0000	0.0000	0.0000
Offal	0	0.0000	0.0000	0.0000
Other vegetables	57	0.0779	0.0779	0.0779
Potatoes	36	0.0560	0.0560	0.0560
Poultry	11	0.0530	0.0530	0.0530
Sugar and preserves <sup>3</sup>	10	0.0098	0.0049	0.0098
<b>Total</b>	<b>102</b>	<b>4.4067</b>	<b>2.9387</b>	<b>2.9387</b>

This is a draft statement for discussion.  
It does not reflect the final views of the Committee and should not be cited.

Food group	Number of Consumers	6.00 to 8.99 months - HBCD 97.5 Exposure (ng/kg bw/d)		
		Alpha	Beta	Gamma
Bread	242	0.1308	0.0872	0.1308
Canned vegetables	131	0.0694	0.0694	0.0694
Carcase meat	217	1.5708	0.0628	0.0628
Cereals	496	0.3714	0.2476	0.2476
Dairy products	535	4.2614	2.8409	2.8409
Eggs	88	0.0536	0.0536	0.0536
Fats+oils	282	0.1218	0.0228	0.0381
Fish	175	0.3599	0.0450	0.0450
Fresh fruit	385	0.1425	0.1425	0.1425
Fruit products	235	0.3054	0.1527	0.2290
Green vegetables	338	0.0751	0.0751	0.0751
Meat products	93	0.5241	0.1048	0.1048
Milk	270	0.1787	0.1787	0.1787
Nuts	19	0.0413	0.0689	0.0413
Offal	6	0.0154	0.0051	0.0051
Other vegetables	453	0.1204	0.1204	0.1204
Potatoes	389	0.1039	0.1039	0.1039
Poultry	252	0.0454	0.0454	0.0454
Sugar and preserves <sup>3</sup>	172	0.0233	0.0116	0.0233
<b>Total</b>	<b>602</b>	<b>4.5038</b>	<b>2.8475</b>	<b>2.8486</b>

Food group	Number of Consumers	9.00 to 11.99 months - HBCD 97.5 Exposure (ng/kg bw/d)		
		Alpha	Beta	Gamma
Bread	502	0.1885	0.1257	0.1885
Canned vegetables	271	0.0860	0.0860	0.0860
Carcase meat	372	1.7640	0.0706	0.0706
Cereals	656	0.4273	0.2849	0.2849
Dairy products	661	3.0097	2.0065	2.0065
Eggs	207	0.0552	0.0552	0.0552
Fats+oils	456	0.1704	0.0319	0.0532
Fish	305	0.4385	0.0548	0.0548
Fresh fruit	574	0.1708	0.1708	0.1708
Fruit products	322	0.3985	0.1993	0.2989
Green vegetables	436	0.0826	0.0826	0.0826
Meat products	262	0.5814	0.1163	0.1163
Milk	426	0.5952	0.5952	0.5952
Nuts	29	0.0699	0.1165	0.0699
Offal	9	0.0655	0.0218	0.0218
Other vegetables	595	0.0998	0.0998	0.0998
Potatoes	546	0.1139	0.1139	0.1139
Poultry	400	0.0482	0.0482	0.0482
Sugar and preserves <sup>3</sup>	297	0.0330	0.0165	0.0330
<b>Total</b>	<b>684</b>	<b>3.7047</b>	<b>2.2458</b>	<b>2.2903</b>